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A COMPARISON OF OSTEOBLAST AND OSTEOCYTE EXPRESSION IN  
HUMAN BONE AND CULTURED MESENCHYMAL STEM CELLS 
JESSICA ROSE CASHEN 
ABSTRACT 
Osteoporosis is an immense and growing health and economic burden of the 
aging population. Its prevalence in both men and women makes it an important target for 
biochemical research and development. A comparative study of the skeletal gene 
expression in native trabecular bone and cartilage tissues to marrow mesenchymal stem 
cells (MSCs) was carried out on tissues and cells obtained from acetabular reaming from 
total hip replacement patients (n=10). The intent of these comparisons was to examine the 
differentiation potential of MSCs grown from the bone marrow that was cultured for 21 
days in three types of media: control media supplemented with fetal bovine serum with 
(CM) and without dexamethasone (CM-D), and an artificial (AFM) devoid of any animal 
product supplementation.  RNA was extracted from these samples, and the bone and 
cartilage, and qRT-PCR was carried out to measure the expression of five genes of 
interest. The genes of interest (COL1A1, RUNX2, SP7, DMP1, and SOST) were chosen 
to respectively assess the progression of cellular and tissue differentiation from MSCs 
into osteocytes.  
There were significant differences in gene expression of RUNX2, SP7, DMP1, 
and SOST between CM, AFM, and bone samples suggesting that each of the culture 
conditions promoted differing amounts of osteogenic differentiation. CM samples were 
relatively undifferentiated compared to the CM-D and AFM cultured cells, and likely 
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contained little or no osteocytes but likely had some amount of osteoblasts. AFM cells 
appeared to be the most differentiated based on comparisons of their expression of 
mRNAs found in osteocytes. Bone and cartilage samples were also tested for the same 
genes of interest. AFM, CM, and CM-D had higher gene expression in markers for 
osteoblasts that are in the process of differentiating, while bone and cartilage showed a 
higher expression of the terminal osteocytic marker. Overall, this study showed that 
artificial media cultured MSCs differentiate at a faster rate than cells grown in the animal 
supplemented media.  
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INTRODUCTION  
 
Bone Physiology 
Bone is a connective tissue that is composed of a calcified extracellular matrix 
and three main types of cells: osteoblasts, osteocytes, and osteoclasts. These three types 
of cells work together to create and maintain the structure of bone, as well as perform 
many other important functions necessary to maintain body homeostasis, including the 
regulation and storage of calcium (Mescher & Junqueira, n.d.).  
Osteoblasts are derived from mesenchymal stem cells (MSCs) and have a number 
of roles in formation and maintenance of the bone (Mescher & Junqueira, n.d.). MSCs are 
important cells throughout the body because of their ability to self-renew, and because 
they are able to differentiate into many kinds of cell throughout the body depending on 
nearby growth factors, these include adipose, cartilage, bone, muscle, tendon, and 
ligament tissues (Almalki & Agrawal, 2016).  MSCs that differentiate into osteoblasts in 
vitro are usually influenced by the growth factors, hormones [dexamethasone] and 
biochemical additives [β-glycerophosphate and ascorbic acid] (Ding, Shyu, & Lin, 2011). 
Once differentiated from MSCs, osteoblasts begin producing the proteins that will form 
the bone matrix, including type I collagen, fibronectin, laminins. As they progress, 
osteoblasts will make more specialized extracellular matrix proteins related to the 
mineralization of their matrix. Additionally, osteoblasts produce both proteases and 
osteoclastogenic factors in order promote osteoclastogenesis. This process is important in 
the homeostatic remodeling of the bones, which repairs and maintains the optimal bone 
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structure (Raggatt & Partridge, 2010). Both MSCs and osteoblasts can be found in 
individuals of any age in the periosteum and endosteum, and on specific trabecular 
surfaces of the bone, meaning that bone cells are turned over and renew throughout an 
individual’s life (De Bari et al., 2006).  
The second prominent cell of bone is the osteocyte. Osteocytes are osteoblasts 
that have been embedded within calcified bone matrix produced during bone formation. 
Osteocytes can communicate to each other long dendritic processes that pass though 
channels in the mineralized matrix called canaliculi. These dendritic process terminate 
with cell to cell contacts through gap junctions (Mescher & Junqueira, n.d.). Osteocytes 
are the most common cells in bone, making up to 90% of the cell population in the tissue. 
They are crucial in monitoring bone homeostasis by regulating both the formation and 
resorption of bone tissue (Bellido, 2014). The presence of viable osteocytes is necessary 
to maintain the integrity of bone. Osteocytes possess mechanosensory mechanisms 
enabling them to sense and respond to loads applied to the bone. They can also detect 
damage to the bone through these mechanosensory mechanisms, and initiate remodeling 
in response to the damage (Bonewald, 2011; Raggatt & Partridge, 2010) .  
The third and final type of bone cell is the osteoclast. Osteoclasts, unlike 
osteoblasts, are derived from the hematopoietic lineage and more specifically come from 
the monocytic arm of the myeloid lineage. Osteoclasts are characteristically large cells 
with multiple nuclei. These cells are the main cell involved in bone resorption and 
remove old, calcified bone matrix (Mescher & Junqueira, n.d.). They are able to do this 
by creating an acidic environment between themselves and the bone which mobilizes the 
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local mineralized matrix. They also produce proteases that degrade matrix proteins that 
become exposed once the mineral has been mobilized (Teitelbaum, 2007). Osteoblasts 
and other cells then take over the space and produce new bone tissue through their own 
mechanisms. This coupled turnover of bone tissue is essential to maintain bone 
homeostasis, and it occurs throughout an individual’s lifespan (Mescher & Junqueira, 
n.d.; Siddiqui & Partridge, 2016). It has been shown that an imbalance in the processes of 
formation and resorption, with an increase in resorption, or a decrease in formation leads 
to an increase in bone fractures due to weakened tissue (Fisher, Fisher, Srikusalanukul, & 
Smith, 2018).   
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Figure 1. Cells of Bone. There are three main cells of bone, osteoblasts, osteocytes, and 
osteoclasts. An example of each is depicted in this image. Balance between each type of 
bone cell is necessary to maintain healthy bone tissue and quality of life (OpenStax 
College, 2013).  
 
There are two ways that the bones of the human body are initially formed during 
fetal development. The first is intramembranous ossification, in which osteoblastic cells 
are formed directly from fetal mesenchymal tissue and begin the process of producing the 
bone matrix and the subsequent formation and calcification of bone tissue. This is the 
way that many of the flat bones of the cranium and facial skeleton are formed. The 
second type of bone formation is endochondral ossification. This is the process which 
forms most of the bones in the body (Mescher & Junqueira, n.d.). This type of formation 
begins with mesenchymal condensation, but differs in that the next step is the 
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differentiation of cells into chondrocytes, which secrete a matrix that will become 
cartilage. This forms a growth plate where the chondrocytes will eventually be replaced 
with bone cells and the bone continues formation from the growth plate (Long & Ornitz, 
2013).  
 
Articular Cartilage 
 There are several types of cartilage in the human body. The cartilage that covers 
the joints of the body is called articular cartilage (AC). AC is avascular and aneural, and 
therefore depends on simple diffusion of oxygen and nutrients to maintain its function. 
This trait allows AC to function to transmit loads, smooth joint articulation, provide wear 
resistance, and facilitate movement, but at the cost of a limited repair function when the 
tissue is damaged. AC is mostly composed of water, but also contains important proteins 
such as type II collagen, proteoglycans, and glycoproteins (S. Chen, Fu, Wu, & Pei, 
2017).  
 
 
 
The Hip Joint 
The hip joint is a ball and socket joint that handles a lot of wear and tear over the 
course of a person’s life. It is designed to support the weight of the human body, which 
means the mobility of the leg is compromised in favor of body stability (Drake, Vogl, & 
Mitchell, 2012). The joint is further stabilized by layers of surrounding muscles and 
 6 
ligaments. The spherical head of the femur and the acetabulum of the pelvis articulate to 
form this joint and are covered with AC, and these two surfaces are especially prone to 
damage over time (Navarro-Zarza et al., 2012).   
 
Osteoporosis 
Osteoporosis is a disease which affects the density of bone and its microstructure, 
which leads to an increased risk of bone fracture (Black & Rosen, 2016). In addition to an 
increased risk of serious injury, osteoporosis also leads to an increased risk of death 
(Gass & Dawson-Hughes, 2006). This can cause changes in quality of life and overall 
health, and makes osteoporosis a serious life-threatening condition (see Figure 2). Further 
insights into this disease could benefit patients diagnosed with osteoporosis for years to 
come. Examples in animal studies have shown that as one ages, there is an imbalance 
between the processes of bone formation and resorption, which leads to a net bone loss 
(Galea et al., 2017). Bone loss is something that can hopefully be prevented in the future, 
especially in those who are genetically predisposed to develop osteoporosis.  
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Figure 2. Effects of Osteoporosis on the Human Body. This image shows the decrease 
in bone mass due to osteoporosis at the level of bone, as well as the effects in posture due 
to such bone loss (“Medical gallery of Blausen Medical 2014,” 2014). 
 
Public Health and Epidemiology  
Osteoporosis is a huge public health concern in around the world. It poses a large 
financial burden, in the United States alone the disease cost patients $19 billion annually, 
not including extra costs including for travel and assisted living. In the European Union, 
it is estimated that the disease costs € 37 billion a year (Curtis, Moon, Harvey, & Cooper, 
2017). This disease is often found in older adults and the population of the United States 
is rapidly aging (Day, 1992). This will lead to a larger population that is prone to 
osteoporosis, and therefore increased risk of fractures and possible death. Currently in the 
United States, 10 million people are living with osteoporosis, and 44 million have low 
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bone density and are at risk for the disease (Elevating Osteoporosis on America’s 
Healthcare Agenda 2 0 1 7 A N N U A L R E P O R T, n.d.). In addition to the personal 
health risks and financial burden patients are also at an increased risk of job loss and 
changes to their working and family lives (Barker, Toye, & Lowe, 2016). These reasons 
make osteoporosis a concern for the public health of the country. If specific genes were 
known to increase risk to osteoporosis, patients with these genes could be identified and 
they could be treated preventively for osteoporosis and could be aware of risks. 
 
 
Figure 3. Percent of United States Population over 65 1950-2050. This graph shows 
the rapidly increasing senior population of the US. Information from UN World 
Population Prospects 2008 (Rcragun, 2009).  
 
In patients over the age of 50, one in three women have been found to develop 
osteoporosis and one in five men will develop the disease (Barker et al., 2016). There 
have been some differences shown between races in addition to the difference between 
sexes. Black women have the highest bone mineral density (BMD), while Asian women 
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have the lowest, and this has been shown in patients of all ages. Generally, most BMD 
differences can be explained by weight differences, this has not been the case for African 
American women, who show no difference in BMD across different weights. When it 
comes to fracture risk, white women and Hispanic women are at the highest risk (Barrett-
Connor et al., 2004) .These demographic differences could be useful in an initial 
diagnosis of osteoporosis.  
 
Diagnosis and Treatment 
There are several stages of severity of osteoporosis. The main factor in 
determining whether someone has the disease is the patient’s bone mineral density 
(BMD) and whether the patient has experienced a fragility fracture. BMD is measured 
using dual energy X-ray absorptiometry (DEXA). There are also web based tools such as 
FRAX ® that can predict risk of osteoporosis by utilizing information from DEXA tests 
as well as demographic information. The FRAX ® algorithm can predict the probability 
that a patient will develop osteoporosis or have a fracture in the next ten years. FRAX ® 
does not require a BMD input, which makes it easy to use and readily available even if a 
patient does not have a DEXA scan (Curtis et al., 2017). Low BMD will lead to a 
diagnosis of osteoporosis (Kanis, Melton, Christiansen, Johnston, & Khaltaev, 2009). 
There are a number of treatment options available for those diagnosed with osteoporosis. 
There are different pharmacological interventions and these are mostly aimed at 
decreasing bone turnover, but can come with unwanted side effects (K. D. Grant, Busse, 
Park, & Baker, 2018). Current antiresorptive drug options include estrogen, selective 
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estrogen receptor modulators (SERMs), calcitonin, bisphosphates, and RANKL 
antibodies. These drugs act to inhibit the disease process of bone resorption. Another 
pharmacological option are anabolic drugs. These include parathyroid hormone (PTH) 
and its analogs. These drugs increase bone formation while keeping bone resorption 
levels low. New directions in drug treatment include sclerostin inhibitors and cathepsin K 
inhibitors. Both of these drugs aim to increase bone mass by inhibiting a crucial signaling 
pathway or protein degradation in bone (Khosla & Hofbauer, 2017).  
 
Risk Factors 
Development of osteoporosis is strongly linked to family history. BMD, which is 
the most important factor in bone fracture and the diagnosis of osteoporosis, as well as 
other factors that influence bone maintenance have been shown to be heritable traits. Due 
to the amount of different traits that can affect the presence of osteoporosis in an 
individual, it is believed that the heritability is polygenic, and no causal genes have been 
identified (Ralston & de Crombrugghe, 2006). The development of osteoporosis is also 
separately influenced by an individual’s age, sex, lifestyle, and pre- or post-menopausal 
state. Lifestyle risk factors include an inadequate intake of calcium and vitamin D, 
physical inactivity, smoking, excessive alcohol consumption, and length of use of cortical 
steroid use (Hendrickx, Boudin, & Van Hul, 2015).  
 
Genetics of Osteoporosis 
A number of different of studies, including association studies, linkage analyses, 
and studies in model organisms, have led to the conclusion that genetics strongly 
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influence the development of osteoporosis (Ralston & de Crombrugghe, 2006). Family 
studies have also shown the significance of genetics, and that the environment less likely 
to play a role in whether someone will be diagnosed with osteoporosis in their lifetime, 
and additionally that multiple genes influence the development of the disease (Guéguen 
et al., 2009).  
The key factor in diagnosing osteoporosis, BMD, has been separately shown to 
have significant genetic influence, which further emphasizes that the genetic component 
of osteoporosis is of great significance (Smith et al., 1973). Twin studies have 
strengthened the evidence for BMD as a heritable trait, and have lead to interest in further 
research into specific DNA studies (Pocock et al., 1987). BMD has been shown to be the 
strongest predictor of risk of fractures, and that men and women with equally low BMDs 
will be effected, so insight into the specific genes which control BMD could give more 
information than the effects of sex or environment or other lifestyle risk factors (Estrada 
et al., 2012; Johnell et al., 2005).  
 
Genetic Regulation 
Transcription of genes is a highly regulated process, and this regulation is specific 
to different tissues within the body. It is very likely that transcription in these different 
tissues is regulated by multiple genes, and identifying these different transcriptional 
regulators could provide specific and valuable insight into etiological causes of tissue 
specific pathologies (Melé et al., 2015). One way to look into the genes that are 
transcribed in a tissue is through the use of RNA-seq. This method can provide insights 
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into what genes are transcribed and can also provide insights about genetic changes from 
disease processes or aging. Sequencing RNA from the tissue of interest provides a 
window into the specific regulation and gene expression of that tissue and this 
information can be used in order to learn more about a disease process and can even be 
used in diagnosis (Cummings et al., 2017).  
 
RT-PCR 
Using the technology of Real Time Polymerase Chain Reaction (RT-PCR) allows 
researchers to easily and accurately assess changes in gene expression. RT-PCR 
technology amplifies complimentary DNA (cDNA) up to 1 million times, which allows 
the study of a small amount of DNA, and in the case of this study, RNA, to be possible.  
(Valasek & Repa, 2005). These reactions are performed in a thermacycler which can 
detect fluorescence levels, and is highly sensitive to the levels of gene amplification. This 
method provides a very measurement of gene expression levels by using a cycle 
threshold (Ct). This threshold is the level at which the fluorescence reaches a detectable 
intensity. This value is also key for understanding the data and reporting gene expression 
levels (Jensen, 2012).    
Use of RT-PCR in this study is crucial and will allow investigation into target 
genes of osteoporosis. RT-PCR has previously been used to study osteoporosis. A study 
used tissues collected during hip replacements to compare the fragility of the bone 
between osteoporotic and osteoarthritic patients, which showed the patients with 
osteoporosis have lower osteoblastic differentiation and activity and is something that 
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will be investigated in this study as well (Giner, Montoya, Vázquez, Miranda, & Pérez-
Cano, 2013). 
 
New Challenges and the Purpose of this Study 
The challenges that we face now in learning more about osteoporosis are 
identifying genes that affect the development of the disease, as well as the mechanisms 
through which they work. One of the aims of this study is to obtain insight into what 
these might be and how widely they are expressed in patients with osteoporosis. This 
study will compare the expression of genes that are known be expressed in osteoblasts 
between samples of human bone and cartilage tissue against bone cells grown in various 
media. Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) will be used to 
measure gene expression from RNA samples of both human tissue and the cultured 
MSCs. 
This is a preliminary study that also aims to compare three different types of cell 
culture media conditions. The main aim of comparing these conditions is to see if one 
type of media is better at producing viable osteocytes from MSCs. Once the ideal media 
is identified, the study can continue using that media to culture all future MSCs.   
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METHODS 
 
Sample Collection  
          All human research was done under a Boston University School of Medicine 
Institutional Research Board Approved protocol: “Bone Tissues Repository”, IRB 
Number: H-35199.  
Femoral heads and acetabular reamings were collected from Boston Medical 
Center patients undergoing total hip replacements. A total of ten patients were included in 
this study, both men and women were included and ranged in age from 51-68 years old. 
Exclusion criteria for subjects in the study include: receiving chemotherapy, sickle cell, 
rheumatoid arthritis, osteoporosis drugs that affect bone metabolism, including Forteo 
(PTH), SERMS, Prolia (Denosumab), and bisphosphonates, and other therapies that can 
modifying bone including anti- TNF and cortical steroids. Before each surgery and 
sample collection, subjects were asked to consent to the study according to HIPAA 
guidelines. Once the femoral head and acetabulum samples were retrieved from the 
patient by the orthopedic surgeon, they were immediately brought back to the lab for 
processing on ice to ensure minimal degradation of tissue. 
 
Table 1. Study Subject Demographics.  
Patient # Sex Age 
203 F 59 
204 F 60 
205 F 51 
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206 M 58 
207 F 61 
208 M 64 
209 M 68 
210 M 53 
211 F 54 
212 F 55 
 
Sample Preparation 
        The sample reamings were obtained from the second and third coring of the 
patient’s acetabulum in order to maximize the amount of bone and cartilage in the 
sample. Once the samples reached the lab they were weighed, and then transferred to a 
new, sterile container using a lab spatula. The reamings were then rinsed with 120ml of 
sterile phosphate buffered saline (PBS). The media was filtered through sterile steel mesh 
into a different sterile container and the remaining tissue sample was washed again with 
100 ml of PBS and then strained. The reamings were rinsed with PBS again to remove all 
non-adherent cells, fat tissues, and blood cells and then was placed into a large petri dish 
on ice. Bone and cartilage fragments were separated from the remaining material using 
forceps. Once the bone and cartilage chips were isolated, they were placed into a 70μm 
filter on a 50ml tube and rinsed with  25 ml of PBS. They were then placed into a sterile 
15ml tube and quickly frozen with liquid nitrogen. Once the sample was frozen, the 
labeled tube was placed into an -80°C degree freezer until further processing.  
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Figure 4. Sample Prep Set-up. Lab bench set up for bone and cartilage extraction from 
acetabular reamings collected from hip replacement surgery.   
 
 
Figure 5. Bone and Cartilage Sample. Example of a typical reaming sample after 
processing for MSCs. The sample is a mixture of bone, cartilage, adipose, and connective 
tissues that need to be separated before further investigation. All sample preparation takes 
place on ice to minimize RNA degradation.  
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Cells from the marrow were plated and grown in 3 types of media: control media 
containing fetal bovine serum with (CM) and without dexamethasone (CM-D), and 
artificial media (AFM) containing no serum or animal derived components. The cells 
were seeded at 12 x10^6 cells/3mm diameter using 6-well cell culture plates (Corning 
Inc., Corning, NY) and grown in a humidified incubator (37° C, 5% CO2). Cells were 
fixed 21 days after plating for an RNA assay that was used for RNA extraction.  
 
RNA Extraction  
 In order to extract RNA from frozen tissue samples, a mortar and pestle was used 
to crush the sample into a fine powder. The sample was kept frozen during this process 
with liquid nitrogen. For cell culture samples, this first step was skipped and samples 
were placed directly into tubes for subsequent tissue dissociation using a Qiagen tissue 
lyser. The powder was then placed into a 2ml tube that contained 0.75ml of Qiazol 
(Qiagen, Cat#79306). A stainless-steel bead was added to the tubes to further lyse the 
bone tissue (Qiagen 5mm Cat#69989). The tubes were placed into pre-cooled metal 
tissue sample holders that were locked into place in the tissue lyser machine (QIAgen 
Tissue Lyser II®). The tissues were lysed for 2 minutes at 30Hz. The sample was then 
transferred to a new tube and 1ml of Qiazol was added. This stood on ice for 2 minutes 
and then 100ul of BCP (Sigma Cat #B9673) was added to the tube. The mixture was 
vortexed, rested on ice, and then was vortexed again. The sample was centrifuged at 
14,000 RPM at 4°C for 15 minutes, then the aqueous phase of the sample was transferred 
to a new tube and an equal volume of isopropanol was added. The sample tube was 
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inverted and then centrifuged again at 14,000 RPM at 4°C for 30 minutes. The 
supernatant was removed and washed with 0.5ml of 100% ethanol and centrifuged at 
14,000 RPM at 4°C for 5 minutes. The ethanol was then removed, and the last step was 
repeated. The ethanol was removed and the remaining pellet of RNA in the tube was left 
to dry. Once dry, the RNA pellet was resuspended in RNAse free water according to the 
size of the pellet and stored at -80°C.  
 
Gel Electrophoresis 
 To assess the success of the RNA extraction, a small amount of the sample was 
run on a 1% agarose gel. 2μl of the RNA sample, 2μl of loading buffer containing 
glycerol, xylene cyanol, and bromophenol (Boston BioProducts), and 8μl of RNAse free 
water was mixed and then pipetted onto the gel. The gel was run at 80V for an hour and 
was then assessed under ultraviolet light for bands indicating 28S and 18S RNA were 
intact in the sample.                                 
 
Figure 6. RNA Samples on Agarose Gel Under UV Light. This figure shows an 
example of the bands that intact RNA samples produce when run on an agarose gel.  
 
RNA Spectrophotometry 
 The concentration of RNA in each sample was determined using a ND-1000 
28S 
18S 
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Spectrophotometer. 1μl of each sample was pipetted onto the pedestal of the Nanodrop 
machine and was measured for sample concentration (ng/ul) and purity ratios 
(260/280nm).  
 
Reverse Transcription  
 The RNA extracted from the human bone, cartilage, and cell culture samples was 
reverse transcribed. 2μg of the RNA sample was added to a microcentrifuge tube and 
diluted with RNase free water to achieve a total volume of 10.4μl. A combination of 
MgCl2 (6.61μl), dNTP mix (6.0μl), 10X RT buffer (3.0μl), random hexamers (1.5μl), 
RNase Inhibitor (0.6μl), and Taqman Reverse Transcriptase (1.89μl) was added to each 
sample tube. The tubes were placed in a thermal cycler (Eppendorf  Mastercycler® 
Personal). The cycles were as follows: 25ᵒ C for 10 minutes, 37ᵒ C for 60 minutes, 95ᵒ C 
for 5 minutes. The resulting complementary DNA (cDNA) was diluted at a ratio of 1:25 
and stored in a freezer at -20C until needed for qRT-PCR.  
 
qRT-PCR 
 The cDNA was used in quantitative Real Time Polymerase Chain Reaction (qRT-
PCR) in order to gain further insight into gene expression in the tissue of interest. 96 well 
plates were loaded with 9 μl of diluted cDNA, 10 μl Universal PCR Master Mix (Applied 
Biosystems®), and 1 μl of a primer set. The wells were then covered with lids and spun 
in a centrifuge at 1,500 RPM for 2 minutes to ensure any bubbles in the samples were 
eliminated before the experiment was run. An Applied Biosystems 7300 Real-Time PCR 
 20 
System was used to perform the qRT-PCR reaction. The reaction cycle ran as 
follows:  50ᵒ C for 2 minutes, 95ᵒ C for 10 minutes, 95ᵒ C for 15 seconds, 60ᵒ C for 1 
minutes for a total of 40 cycles. 2 wells were run for each sample and the average of the 
two wells were normalized to 18S RNA to produce a ΔCt value. If a sample had an 
undetectable level of the gene of interest in qRT-PCR measurements, a value of 40 was 
assigned. This value indicates that the level of the gene is very low and allowed the 
calculation of a ΔCt value when it otherwise would not produce one. The ΔCt of the 
experimental media was compared to the ΔCt of the control media to produce a ΔΔCt 
value. This value was then log transformed to find the gene fold expression of the 
experimental media compared to the control media. 
 
Table 2. DNA Primers Used in qRT-PCR and Expression IDs. The primers of six 
genes of interest and their corresponding assay IDs are listed. All primers were purchased 
from Thermo Fisher Scientific, Waltham, MA.  
Genes Taqman Expression ID 
18S RNA Hs03928990 
COL1A1 Hs01076777 
RUNX2 Hs00231692 
SP7  Hs00541729 
DMP1  Hs00189368 
SOST Hs00228830 
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Statistical Analysis 
The normalized ΔCt values were used to find mean gene expression in relation to 
18S RNA. To determine whether mean expression varied significantly for each gene 
across different media, 2-way analysis of variance (ANOVA) tests were used to compare 
ΔCt values between different patients and media. Two tailed t tests were used to compare 
the means between media and bone and cartilage samples. A p-value less than 0.05 was 
considered significant for all statistical analyses.  
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RESULTS 
 
Patient Demographics 
Data was collected from a group of ten hip replacement patients at Boston 
Medical Center (Table X). The sample group was made up of mostly female patients 
(F=6, M=4). The patients ranged in age from 51-68 years old (mean=58.3, standard 
deviation=5.25). Patients are indicated by numbers 203 through 212.  
 
COL1A1 
COL1A1 is a widely expressed gene that codes for collagen and is expected to 
have a high expression in most samples. The results of a 2-way ANOVA show that there 
is no significant difference between all media and no significant difference between 
patients for COL1A1 gene expression (p= 0.15, F= 1.79; p= 0.26, F=2.49). Results of 
two tailed T tests for differences between CM and CM-D, CM and AFM, and CM and 
human bone samples were not significant (p=0.22, t=1.27; p=0.16, t=1.48; p=0.70, t=-
0.39). There was no difference in a T test between bone and cartilage expression of 
COL1A1 (p=0.37, t=-0.94). ΔCt values were log transformed and plotted in Figure 8. 
Each dot in the graph represents a sample, this method will be used to represent gene 
expression for all genes of interest. Figure 8 shows that AFM had the highest relative 
COL1A1 expression compared to other samples.  
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Figure 7. COL1A1 Expression Relative to 18S RNA. This graph shows the distribution 
of COL1A1 expression across various media and sample types measured with qRT-PCR. 
Expression values were normalized to 18S RNA expression values to achieve a ΔCt value 
which was then log transformed to produce comparable data points. 
 
 
RUNX2 
RUNX2 is the next gene of interest that was studied. The results of a 2-way 
ANOVA show that there is no significant difference between all media and no significant 
difference between patients for RUNX2 gene expression measured by qRT-PCR (p=0.76, 
F=0.27; p=0.21, F=1.59). Results of two tailed T tests for differences between CM and 
CM-D and CM and AFM were not significant (p=0.44, t=-0.79; p=0.64, t=-0.49). There 
was a significant difference in RUNX2 expression between CM samples and human bone 
tissue samples (p<0.01, t=-3.84). There was no difference between RUNX2 expression in 
human bone and cartilage samples (p=0.69, t=-0.42). AFM and cartilage samples showed  
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the highest and lowest relative RUNX2 expression, respectively. Figure 9 plots the 
distribution of RUNX2 expression for all samples, and shows the relatively higher 
expression in cultured cells over human bone and cartilage tissues.   
 
 
Figure 8. RUNX2 Expression Relative to 18S RNA. This graph shows the distribution 
of RUNX2 expression across various media and sample types measured with qRT-PCR. 
Expression values were normalized to 18S RNA expression values to achieve a ΔCt value 
which was then log transformed to produce comparable data points.  
 
SP7 
The next gene of interest in the lineage is SP7, expression levels of this gene will 
start to give a picture of how many samples have MSCs differentiating into osteoblasts. 
The results of a 2-way ANOVA show that there is a significant difference between all 
media conditions for SP7 expression (p<0.01, F=7.09), and that there is no difference 
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between all patients (p=0.15, F=2.54). Results of two tailed T tests for differences 
between CM and CM-D were not significant (p=0.44, t=0.79). However, there was a 
significant difference between CM and AFM SP7 expression and a difference between 
CM and bone SP7 expression (p<0.05, t=2.6; p<0.01; t=3.57). There was no difference 
between SP7 expression in human bone and cartilage samples (p=0.52, t=-0.66). These 
results show that CM-D and AFM plated cells seem to be differentiating into osteoblasts. 
Figure 10 shows more CM-D and AFM samples with higher expression, whereas CM 
samples remain relatively low in their relative SP7 expression.  
 
 
Figure 9. SP7 Expression Relative to 18S RNA.This graph shows the distribution of 
SP7 expression across various media and sample types measured with qRT-PCR. 
Expression values were normalized to 18S RNA expression values to achieve a ΔCt value 
which was then log transformed to produce comparable data points. 
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DMP1 
DMP1 is a protein that will indicate if samples have reached the osteocyte stage. 
A 2-way ANOVA showed that there was a significant difference between all media 
conditions for DMP1 expression (p<0.01, F=9.68), and that there is no difference 
between patients (p=0.43, F=1.06). Results of two tailed T tests for differences of DMP1 
expression between CM and CM-D were not significant (p=0.57, t=0.58). There was a 
significant difference between CM and AFM DMP1 expression, and between CM and 
bone expression (p<0.01, t=3.27; p<0.05, t=2.55). There was no difference between SP7 
expression in human bone and cartilage samples (p=0.61, t=-0.52). AFM had the highest 
mean level of DMP1 expression, and likely has some osteoblasts differentiating into 
osteocytes. As Figure 11 shows, AFM samples are expressing higher relative levels of 
DMP1 compared to the other media. It also shows that bone and cartilage samples are 
expressing higher levels than some media samples.    
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Figure 10. DMP1 Expression Relative to 18S RNA. This graph shows the distribution 
of DMP1 expression across various media and sample types measured with qRT-PCR. 
Expression values were normalized to 18S RNA expression values to achieve a ΔCt value 
which was then log transformed to produce comparable data points. 
 
SOST 
SOST is the final gene of interest that was tested and will indicate which samples, 
if any, are the most differentiated in the osteocyte lineage. A 2-way ANOVA showed that 
there was a significant difference between media for SOST expression (p<0.05, F=4.02), 
and that there was no difference between patients (p=0.26, F=1.46). Results of two tailed 
T tests for differences in SOST expression between CM and CM-D and differences 
between CM and AFM were not significant (p=0.22, t=1.27; p=0.89, t=0.14). There was 
a difference in SOST relative expression for CM and human bone samples (p<0.05, 
t=2.74). There was no difference between SP7 expression in human bone and cartilage 
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samples (p=0.83, t=-0.22). This is the only gene where AFM does not have the highest 
expression, suggesting that AFM has a lower level of osteocytes. Figure 12 illustrates the 
overall very low levels of SOST in all samples, and highlights the similar levels of SOST 
across the three media types. The distribution of bone and cartilage samples, with a 
slightly higher level of expression, is also emphasized by Figure 12.   
Overall, the general trend for most samples’ relative mean expression was a 
decrease in the level of the gene of interest, shown in Table 4. AFM generally had the 
greatest relative expression, while CM generally had the lowest.   
 
 
Figure 11. SOST Expression Relative to 18S. This graph shows the distribution of 
SOST expression across various media and sample types measured with qRT-PCR. 
Expression values were normalized to 18S RNA expression values to achieve a ΔCt value 
which was then log transformed to produce comparable data points 
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Table 3. Mean ΔCt Values for All Samples. Mean ΔCt values for all sample groups and 
genes of interest with standard deviations.  
Genes CM CM-D AFM Bone Cartilage 
COL1A1 9.46±2.7 8.06±2.1 7.69±2.5 9.87±1.8 10.89±2.4 
RUNX2 12.5±0.9 13.05±1.8 12.8±1.9 14.9±1.7 15.8±4.6 
SP7 22.9±1.5 21.4±2.3 18.6±3.7 18.2±3.0 19.13±2.8 
DMP1 25.32±0.7 23.79±2.9 19.44±4.1 21.10±3.1 21.9±3.0 
SOST 25.34±0.9 23.02±2.5 24.38±1.6 21.19±2.5 21.46±2.3 
 
Table 4. Mean Log Transformed ΔCt Values for All Samples. Mean 2^(-ΔCt) values 
for all sample groups and genes of interest with standard deviations. 
Genes CM CM-D AFM Bone Cartilage 
COL1A1 
0.0028 
±0.002 
0.0064  
±0.004 
0.011  
±0.01 
0.0020 
±0.02 
0.0018 
±0.003 
RUNX2 
2.0E-4 
±9.9E-5 
0.00021 
±0.0002 
0.00049 
±0.001 
5.7E-5 
±6.3E-5 
0.0031 
±0.008 
SP7 
1.9E-7 
±1.8E-7 
9.7E-7  
±1.7E-7 
1.1E-5 
±1.9E-5 
1.3E-5 
±2.6E-5 
6.2E-6 
±1.1E-5 
DMP1 
2.6E-8 
±1.2E-8 
3.2E-7  
±5.6E-7 
2.2E-5 
±5.9E-5 
2.4E-6 
±4.3E-6 
1.2E-6 
±1.9E-6 
SOST 
2.8E-8 
±1.9E-8 
3.6E-7  
±5.4E-7 
8.0E-8 
±8.5E-8 
2.0E-6 
±4.4E-6 
1.0E-6 
±1.8E-6 
 
ΔΔCt Comparisons 
The ΔΔCt value is an important calculation because it shows how much more or 
less the gene of interest is expressed in the experimental group compared to the control 
group, which for the purpose of these calculations was CM. A value less than one for the 
sample group indicates that the control has a higher expression of the gene of interest, 
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and ΔΔCt value greater than one indicates the comparison group has the higher 
expression, and at what fold level. ΔΔCt calculations for our genes of interest show a 
general increase in gene fold expression of COL1A1, RUNX2, SP7, DMP1, and SOST in 
both CM-D (Figure 13A and 13B) and AFM (Figure 14A and 14B) media compared to 
the control media. For these calculations and graphs, patient 208 COL1A1 samples were 
not used because they were greater than two standard deviations from the mean, and was 
an extreme outlier.   
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Figure 12. Gene Fold Expression Changes of CM-D Samples Compared to CM 
Samples. (A. All Samples B. Zoomed in View of Graph) Gene fold expression was 
calculated using the ΔΔCt method from expression levels obtained with qRT-PCR and 
shows the gene expression of CM-D compared to CM samples.  
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Figure 13. Gene Fold Expression Changes of AFM Samples Compared to CM 
Samples. (A. All Samples B. Zoomed in View of Graph) Gene fold expression was 
calculated using the ΔΔCt method from expression levels obtained with qRT-PCR and 
shows the gene expression of AFM compared to CM samples.  
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Table 5. Mean ΔΔCt Values for All Samples. Means and standard deviations of ΔΔCt 
values obtained from qRT-PCR. CM values are 1 and CM-D and AFM values are either 
greater or lesser than one to indicate whether they express greater or lesser amounts of 
the gene of interest, and at what level.  
Genes CM CM-D AFM 
COL1A1 1 97.42±286 105.8±294 
RUNX2 1 1.41±1.1 3.21±5.4 
SP7 1 6.99±12.0 29.29±61.4 
DMP1 1 19.66±49.8 111.27±146 
SOST 1 20.72±49.6 4.70±6.1 
 
Table 6. Statistical Summary. A summary of significant differences in gene expression 
for each gene of interest between the different sample groups. * = p<0.05, **=p<0.01, 
ns=not significant, p>0.05 
Groups COL1A1 RUNX2 SP7 DMP1 SOST 
All Media ns ns ** ** * 
CM vs. CM-D ns ns ns ns ns 
CM vs. AFM ns ns * * ns 
CM vs. Bone ns * ** * * 
Bone vs. Cartilage  ns ns ns ns ns 
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DISCUSSION 
 
Several genes of interest were compared in this study. Each was chosen because 
of the role it plays in bone regulation and possible relation to osteoporosis pathology. The 
expression of these genes was used to assess the differentiation state of marrow 
mesenchymal stem cells grown in tissue culture under differing conditions. Each gene is 
expressed at different levels during the differentiation of MSCs into osteoblasts and then 
into osteocytes. 
 
COL1A1 
COL1A1 encodes collagen I, which is the major protein of human bones. 
Polymorphisms occurring in COL1A1 result in low bone mass, indicating the important 
role this gene plays in bone and cartilage tissues (S. F. A. Grant et al., 1996). We 
expected to see the highest expression of this gene compared to other genes of interest in 
both human samples and cultured cells, and across all media types. COL1A1 is often 
used as a positive control for osteoblastic differentiation (Hsu, Hsu, Hung, Shen, & Hsu, 
2018). All cell culture samples tested in this study had at least some expression of 
COL1A1, so we can tell that at least some MSCs began the osteoblastic differentiation 
path, other genes tested will indicate how far down the path the cells are, and will be 
discussed further.  
AFM had the lowest mean ΔCt value for COL1A1, and therefore the highest 
relative expression of this gene. The human tissue samples had the highest ΔCts, and the 
lowest relative gene expression. There were no significant differences between media 
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when it came to ΔCt measurements of COL1A1. This is likely because COL1A1 is a 
highly prevalent gene and is the first gene in the path of osteoblastogenesis so all samples 
are producing this at a relatively high rate. The ΔΔCt values showed that both CM-D and 
AFM samples had increased expression of COL1A1 compared to the CM, and both were 
one of the largest fold increases of any gene tested. This could show that both samples 
are producing more cells that are ready to enter the osteoblast stage.  
 
RUNX2 
RUNX2 is the next gene of interest in the pathway and is the initial transcriptional 
determinant of osteogenic differentiation from MSCs (Komori, 2009). This transcription 
factor is required for osteoblastogenesis to occur in both endochondral and 
intramembranous ossification. It is also necessary for proper function of mature 
osteoblasts as well as terminal hypertophic differentiation of chondrocytes during tissue 
mineralization. This makes this specific transcription factor an important measure 
because it can provide insight as to whether the bone tissue still has osteoblastic activity, 
and if the bone tissue is still actively turning over (Giner et al., 2013). Since RUNX2 is 
also crucial for chondrocyte hypertrophy, so we can expect to see some level of RUNX2 
expression in the cartilage samples (Long & Ornitz, 2013).  
 There were no significant differences in levels of RUNX2 between any media 
conditions or human tissue samples. This is likely because RUNX2 is so prevalent in 
different types of cells and stages of development of those cells, as discussed above. All 
samples have a higher mean 2^(-ΔCt) value for COL1A1 than RUNX2, showing that 
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RUNX2 expression is relatively lower in all samples. This is further backed up by 
looking at log transformed ΔCt values for all samples, CM, CM-D, and AFM values are 
generally all clustered around the same values and therefore have similar relative 
expression of RUNX2 compared to 18S RNA.  
ΔΔCt values showed an increase in gene fold expression for both CM-D and 
AFM compared to CM samples. This was the lowest fold increase of any gene of interest 
in this study. This could show that CM samples are achieving entry into the osteoblast 
lineage and are mainly in the osteoblast stage at 21 days, and are producing higher levels 
of RUNX2. These results point to CM samples being in an early stage of 
osteoblastogenesis with high RUNX2 expression, while other samples are further along 
in the lineage with lower RUNX2 expression.  
 
SP7 
SP7, also known as osterix (OSX), is a transcription factor that is required for 
osteoblast differentiation and bone formation. Mice with SP7 knockouts do not form 
bone, even if RUNX2 is present, which leads to the conclusion that SP7 is downstream 
from RUNX2 in the differentiation path (Long & Ornitz, 2013). SP7 is expressed in 
osteoblasts and in some chondrocytes, and expression in osteoblasts increases as 
differentiation occurs (Peng et al., 2013). SP7 is expressed during initial bone 
development, but is also expressed at significant levels throughout the life of the bone, 
indicating that the gene is important for bone homeostasis and maintenance. This would 
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also indicate that age should not have as strong as an effect on SP7 expression as it does 
on some of our other genes of interest (Zhou et al., 2010).  
SP7 is the first gene in the differentiation pathway that showed a significant 
difference between different cell culture media samples. There was a significant 
difference between the CM and AFM samples. From this we can conclude that the media 
is making a difference in the level of differentiation that the MSCs are able to achieve at 
21 days. CM had the lowest relative expression of this gene, even compared to human 
tissue samples, so at 21 days CM is in the RUNX2 osteoblastogenesis phase, and 
differentiates slower than AFM samples. AFM and CM-D both had an increase in fold 
expression over CM samples for SP7, however AFM had a much larger increase and 
strengthens the claims that cells in AFM are differentiating faster than cells in the other 
two types of media.  
 
DMP1 
Dentin Matrix Protein 1 (DMP1) is a protein that is required for mineralization of 
skeletal bone as well as dentin in teeth. It is highly expressed in osteocytes and is critical 
for osteocyte differentiation (Toyosawa et al., 2001). Mice lacking DMP1 have little or 
poor mineralization of bone and teeth. Humans with mutations of DMP1 will often 
present with hypophosphatemic rickets, a disorder of phosphate homeostasis. DMP1 is 
found in both early and mature osteocytes so we can expect to see expression of this 
protein in samples that are just starting to differentiate, as well as in samples that have 
reached the end of the osteocyte lineage (Inagaki et al., 2015).  
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 There was a significant difference noted between DMP1 expression in CM and 
AFM. There was a 100-fold increase in AFM DMP1 expression compared to CM. AFM 
also has the highest relative expression of DMP1, indicating that some number of cells 
grown in AFM are differentiating from osteoblasts into osteocytes. Human bone samples 
also have a higher relative expression of DMP1 than CM samples, which suggests that 
CM samples are not as differentiated as human bone or AFM cells. CM-D had a large 
fold increase compared to CM, as well. These findings further indicate that the CM 
samples have not moved as far down the lineage as either the CM-D or AFM samples. 
CM samples could be more slowly differentiating, or something could have happened 
with the CM samples that has limited their ability to differentiate past the osteoblast 
stage.  
 
SOST 
 SOST is responsible for the production of sclerostin, which is produced by 
osteocytes. Its primary role is to inhibit bone formation. If SOST is nonfunctional, it can 
result in undetectable sclerostin and produces a phenotype of sclerosteosis and hand 
abnormalities (Sebastian & Loots, 2017). SP7 and RUNX2 are known to activate the 
expression of SOST and the production of sclerostin (Pérez-Campo et al., 2016). SOST is 
the final gene in the path of differentiation that has been studied in this experiment. 
Samples with SOST expression are the most differentiated, and samples with no 
expression or little expression of SOST have likely not yet reached the osteocyte stage or 
were unable to differentiate that far in the lineage. It is a possibility that samples were 
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impaired in sclerostin production simply because of the age of the patients that cells were 
obtained from. Studies have shown that SOST production is significantly less in older 
individuals (Kwan et al., 2011).  
Statistical analyses showed a difference between all media conditions for relative 
SOST expression, and a difference between the CM and bone samples. In fact, human 
bone had the overall highest relative expression of SOST in this study, which would be 
expected because many cells of adult bone are at the terminal stage of the osteocyte 
lineage. Some cells grown from the MSCs might have reached the point of sclerostin 
production, but it is unlikely that they could have gotten to a similar level as fully formed 
bone tissue.  
The ΔΔCt values for both CM-D and AFM showed an increase in fold expression 
over CM. From this we can predict that CM-D and AFM cells are both further 
differentiated than CM cultured cells. This further backs up evidence from DMP1 results 
that CM samples had little or no osteocytes, and are likely made up mostly of MSCs and 
osteoblasts.  
It is interesting to note that SOST has been found in some osteoblasts and 
chondrocytes in some studies (Delgado-Calle, Sato, & Bellido, 2017). This could explain 
the similar levels of SOST in human bone and cartilage samples. Since SOST is 
unpredictable in its expression, SP7 and DMP1 could give a bit more insight into the 
actual level of differentiation of the cells when it comes to comparison across different 
media.  
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Control Media without Dexamethasone  
In order to properly grow MSCs into viable osteoblasts, stem cells should be 
cultured with dexamethasone (DEX), ascorbic acid, and beta-glycerophosphate (Q. Chen 
et al., 2016). DEX accelerates osteoblastic activity, although too high of a dose can 
induce apoptosis. A low level of DEX has been shown to increase cell viability (Zhang, 
Liu, & Liang, 2018). Our study did not find a significant difference in osteoblastic or 
osteocytic markers between cells grown in the control media and control media without 
DEX. Our CM-D samples did, however, show an increase in fold expression over CM for 
all genes of interest, which was unexpected. These unexpected results could be due to the 
small sample size used in this study. Additionally, the MSCs were harvested from the 
acetabular reamings of patients undergoing total hip replacements for various reasons. 
Any of the health conditions that the patients have, including osteoporosis or obesity, 
could have had an unknown effect on gene expression and affected any of the cells plated 
in any of the media. Other issues in plating and growing the control media cells so that 
they did not become as differentiated as CM-D or AFM could have occurred over the 
course of the study as well.   
 
Bone and Cartilage 
As an individual ages, bone marrow increases in adiposity because more MSCs 
are directed to the adipocyte lineage instead of the osteoblastic lineage. This could 
account for the decrease in osteocyte differentiation in human tissue samples in older 
patients, and possible gene expression abnormalities (H.-T. Chen et al., 2012). There 
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were no significant differences found between any of the bone and cartilage samples for 
any gene. This could be due to issues with methods, such as bone tissue not being 
completely separated from cartilage tissue, or issues with samples themselves. The age 
range of patients is skewed older, and this could affect the gene expression values that we 
expect to find. As one ages, transcriptional noise increases and can cause changes in gene 
transcription (López-Otín, Blasco, Partridge, Serrano, & Kroemer, 2013). This could also 
affect the expression of these genes involved in the osteoblastogenesis pathway. As 
mentioned above, disease processes of the bone and cartilage, such as osteoporosis, likely 
affected the expression of our genes of interest.  
 
Conclusions and Future Directions 
The results indicated that an ideal media to grow marrow derived stem cells into 
differentiated osteocytes is artificial media. The AFM had a higher mean 2^(-ΔCt) value 
for most genes of interest, and was significantly higher in expression for SP7 and DMP1, 
which are markers of osteocyte activity.  
The patient population of this study had a mean age of 58.3 years. Previous 
studies have shown that MSCs obtained from bone marrow have a decreased potential to 
proliferate and differentiate as patients age (Yu et al., 2011). This should be taken into 
consideration for future studies and offers an interesting road for future analysis of these 
patients’ gene expression. Further limitations of this study include the methods with 
which human bone and cartilage samples were prepped. In the future, it could be useful 
to be more specific in separating bone and cartilage tissue to ensure that there is no 
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crossover of this tissues or contamination by blood or fat tissues that are present in the 
original reaming sample. This could be achieved through use of a dissecting microscope 
and additional prep work, such as more washes before the sample is frozen. Another way 
to check for contamination of tissues would be to include more markers in the qRT-PCR 
analysis, including hematopoietic markers and markers specific for cartilage.   
Future studies should continue to look at the expression levels of these genes and 
more to determine what role they play in the process of osteoporosis and should look into 
possible future directions for treatment and preventative health care measures in order to 
make osteoporosis a less prevalent and less life threatening condition.   
 
 
 
 
 
 
 
 
 
 
  
 43 
REFERENCES 
 
Almalki, S. G., & Agrawal, D. K. (2016). Key transcription factors in the differentiation 
of mesenchymal stem cells. Differentiation; Research in Biological Diversity, 92(1–
2), 41–51. https://doi.org/10.1016/j.diff.2016.02.005 
Barker, K. L., Toye, F., & Lowe, C. J. M. (2016). A qualitative systematic review of 
patients’ experience of osteoporosis using meta-ethnography. Archives of 
Osteoporosis, 11(1), 33. https://doi.org/10.1007/s11657-016-0286-z 
Barrett-Connor, E., Siris, E. S., Wehren, L. E., Miller, P. D., Abbott, T. A., Berger, M. L., 
… Sherwood, L. M. (2004). Osteoporosis and Fracture Risk in Women of Different 
Ethnic Groups. Journal of Bone and Mineral Research, 20(2), 185–194. 
https://doi.org/10.1359/JBMR.041007 
Bellido, T. (2014). Osteocyte-driven bone remodeling. Calcified Tissue International, 
94(1), 25–34. https://doi.org/10.1007/s00223-013-9774-y 
Black, D. M., & Rosen, C. J. (2016). Postmenopausal Osteoporosis. New England 
Journal of Medicine, 374(3), 254–262. https://doi.org/10.1056/NEJMcp1513724 
Bonewald, L. F. (2011). The amazing osteocyte. Journal of Bone and Mineral Research : 
The Official Journal of the American Society for Bone and Mineral Research, 26(2), 
229–238. https://doi.org/10.1002/jbmr.320 
Chen, H.-T., Lee, M.-J., Chen, C.-H., Chuang, S.-C., Chang, L.-F., Ho, M.-L., … Chang, 
J.-K. (2012). Proliferation and differentiation potential of human adipose-derived 
mesenchymal stem cells isolated from elderly patients with osteoporotic fractures. 
Journal of Cellular and Molecular Medicine, 16(3), 582–593. 
 44 
https://doi.org/10.1111/j.1582-4934.2011.01335.x 
Chen, Q., Shou, P., Zheng, C., Jiang, M., Cao, G., Yang, Q., … Shi, Y. (2016). Fate 
decision of mesenchymal stem cells: adipocytes or osteoblasts? Cell Death and 
Differentiation, 23(7), 1128–1139. https://doi.org/10.1038/cdd.2015.168 
Chen, S., Fu, P., Wu, H., & Pei, M. (2017). Meniscus, articular cartilage and nucleus 
pulposus: a comparative review of cartilage-like tissues in anatomy, development 
and function. Cell and Tissue Research, 370(1), 53–70. 
https://doi.org/10.1007/s00441-017-2613-0 
Cummings, B. B., Marshall, J. L., Tukiainen, T., Lek, M., Donkervoort, S., Foley, A. R., 
… MacArthur, D. G. (2017). Improving genetic diagnosis in Mendelian disease with 
transcriptome sequencing. Science Translational Medicine, 9(386). 
https://doi.org/10.1126/scitranslmed.aal5209 
Curtis, E. M., Moon, R. J., Harvey, N. C., & Cooper, C. (2017). The impact of fragility 
fracture and approaches to osteoporosis risk assessment worldwide. Bone, 104, 29–
38. https://doi.org/10.1016/j.bone.2017.01.024 
Day, J. C. (1992). Population Projections of the United States, by Age, Sex, Race, and 
Hispanic ... - Jennifer Cheeseman Day - Google Books (Volume 3). U.S. 
Department of Commerce, Economics and Statistics Administration, Bureau of the 
Census. Retrieved from 
https://books.google.com/books?id=DPMxFHfqNbAC&lr=&source=gbs_navlinks_
s 
De Bari, C., Dell’Accio, F., Vanlauwe, J., Eyckmans, J., Khan, I. M., Archer, C. W., … 
 45 
Luyten, F. P. (2006). Mesenchymal multipotency of adult human periosteal cells 
demonstrated by single-cell lineage analysis. Arthritis & Rheumatism, 54(4), 1209–
1221. https://doi.org/10.1002/art.21753 
Delgado-Calle, J., Sato, A. Y., & Bellido, T. (2017). Role and mechanism of action of 
sclerostin in bone. Bone, 96, 29–37. https://doi.org/10.1016/j.bone.2016.10.007 
Ding, D.-C., Shyu, W.-C., & Lin, S.-Z. (2011). Mesenchymal Stem Cells. Cell 
Transplantation, 20(1), 5–14. https://doi.org/10.3727/096368910X 
Drake, R. L., Vogl, A. W., & Mitchell, A. W. M. (2012). Gray’s Basic Anatomy. 
Philadelphia: Elsevier. 
Elevating Osteoporosis on America’s Healthcare Agenda 2 0 1 7 A N N U A L R E P O R 
T. (n.d.). Retrieved from https://cdn.nof.org/wp-
content/uploads/2017_NOF_Annual_report_v6_final.pdf 
Estrada, K., Styrkarsdottir, U., Evangelou, E., Hsu, Y.-H., Duncan, E. L., Ntzani, E. E., 
… Rivadeneira, F. (2012). Genome-wide meta-analysis identifies 56 bone mineral 
density loci and reveals 14 loci associated with risk of fracture. Nature Genetics, 
44(5), 491–501. https://doi.org/10.1038/ng.2249 
Fisher, A., Fisher, L., Srikusalanukul, W., & Smith, P. N. (2018). Bone Turnover Status: 
Classification Model and Clinical Implications. International Journal of Medical 
Sciences, 15(4), 323–338. https://doi.org/10.7150/ijms.22747 
Galea, G. L., Meakin, L. B., Harris, M. A., Delisser, P. J., Lanyon, L. E., Harris, S. E., & 
Price, J. S. (2017). Old age and the associated impairment of bones’ adaptation to 
loading are associated with transcriptomic changes in cellular metabolism, cell-
 46 
matrix interactions and the cell cycle. Gene, 599, 36–52. 
https://doi.org/10.1016/j.gene.2016.11.006 
Gass, M., & Dawson-Hughes, B. (2006). Preventing Osteoporosis-Related Fractures: An 
Overview. The American Journal of Medicine, 119(4), S3–S11. 
https://doi.org/10.1016/j.amjmed.2005.12.017 
Giner, M., Montoya, M. J., Vázquez, M. A., Miranda, C., & Pérez-Cano, R. (2013). 
Differences in osteogenic and apoptotic genes between osteoporotic and 
osteoarthritic patients. BMC Musculoskeletal Disorders, 14, 41. 
https://doi.org/10.1186/1471-2474-14-41 
Grant, K. D., Busse, E. C., Park, D. K., & Baker, K. C. (2018). Internal Fixation of 
Osteoporotic Bone. Journal of the American Academy of Orthopaedic Surgeons, 
26(5), 166–174. https://doi.org/10.5435/JAAOS-D-16-00142 
Grant, S. F. A., Reid, D. M., Blake, G., Herd, R., Fogelman, I., & Ralston, S. H. (1996). 
Reduced bone density and osteoporosis associated with a polymorphic Sp1 binding 
site in the collagen type I α 1 gene. Nature Genetics, 14(2), 203–205. 
https://doi.org/10.1038/ng1096-203 
Guéguen, R., Jouanny, P., Guillemin, F., Kuntz, C., Pourel, J., & Siest, G. (2009). 
Segregation analysis and variance components analysis of bone mineral density in 
healthy families. Journal of Bone and Mineral Research, 10(12), 2017–2022. 
https://doi.org/10.1002/jbmr.5650101223 
Hendrickx, G., Boudin, E., & Van Hul, W. (2015). A look behind the scenes: the risk and 
pathogenesis of primary osteoporosis. Nature Reviews Rheumatology, 11(8), 462–
 47 
474. https://doi.org/10.1038/nrrheum.2015.48 
Hsu, W.-B., Hsu, W.-H., Hung, J.-S., Shen, W.-J., & Hsu, R. W.-W. (2018). 
Transcriptome analysis of osteoblasts in an ovariectomized mouse model in 
response to physical exercise. Bone & Joint Research, 7(11), 601–608. 
https://doi.org/10.1302/2046-3758.711.BJR-2018-0075.R2 
Inagaki, Y., Kashima, T. G., Hookway, E. S., Tanaka, Y., Hassan, A. B., Oppermann, U., 
& Athanasou, N. A. (2015). Dentine matrix protein 1 (DMP-1) is a marker of bone 
formation and mineralisation in soft tissue tumours. Virchows Archiv, 466(4), 445–
452. https://doi.org/10.1007/s00428-014-1706-3 
Jensen, E. C. (2012). Real-Time Reverse Transcription Polymerase Chain Reaction to 
Measure mRNA: Use, Limitations, and Presentation of Results. The Anatomical 
Record: Advances in Integrative Anatomy and Evolutionary Biology, 295(1), 1–3. 
https://doi.org/10.1002/ar.21487 
Johnell, O., Kanis, J. A., Oden, A., Johansson, H., De Laet, C., Delmas, P., … 
Tenenhouse, A. (2005). Predictive Value of BMD for Hip and Other Fractures. 
Journal of Bone and Mineral Research, 20(7), 1185–1194. 
https://doi.org/10.1359/JBMR.050304 
Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (2009). The 
diagnosis of osteoporosis. Journal of Bone and Mineral Research, 9(8), 1137–1141. 
https://doi.org/10.1002/jbmr.5650090802 
Khosla, S., & Hofbauer, L. C. (2017). Osteoporosis treatment: recent developments and 
ongoing challenges. The Lancet. Diabetes & Endocrinology, 5(11), 898–907. 
 48 
https://doi.org/10.1016/S2213-8587(17)30188-2 
Komori, T. (2009). Regulation of Osteoblast Differentiation by Runx2 (pp. 43–49). 
Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-1050-9_5 
Kwan, M. D., Quarto, N., Gupta, D. M., Slater, B. J., Wan, D. C., & Longaker, M. T. 
(2011). Differential expression of sclerostin in adult and juvenile mouse calvariae. 
Plastic and Reconstructive Surgery, 127(2), 595–602. 
https://doi.org/10.1097/PRS.0b013e3181fed60d 
Long, F., & Ornitz, D. M. (2013). Development of the endochondral skeleton. Cold 
Spring Harbor Perspectives in Biology, 5(1), a008334. 
https://doi.org/10.1101/cshperspect.a008334 
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The 
hallmarks of aging. Cell, 153(6), 1194–1217. 
https://doi.org/10.1016/j.cell.2013.05.039 
Medical gallery of Blausen Medical 2014. (2014). WikiJournal of Medicine, 1(2). 
https://doi.org/10.15347/wjm/2014.010 
Melé, M., Ferreira, P. G., Reverter, F., DeLuca, D. S., Monlong, J., Sammeth, M., … 
Guigó, R. (2015). Human genomics. The human transcriptome across tissues and 
individuals. Science (New York, N.Y.), 348(6235), 660–665. 
https://doi.org/10.1126/science.aaa0355 
Mescher, A. L., & Junqueira, L. C. U. (n.d.). Junqueira’s basic histology : text and atlas. 
Navarro-Zarza, J. E., Villaseñor-Ovies, P., Vargas, A., Canoso, J. J., Chiapas-Gasca, K., 
Hernández-Díaz, C., … Kalish, R. A. (2012). Clinical Anatomy of the Pelvis and 
 49 
Hip. Reumatología Clínica, 8, 33–38. https://doi.org/10.1016/j.reuma.2012.10.006 
OpenStax. (2016). Oateoarthritis Hip. Retrieved March 18, 2019, from 
https://commons.wikimedia.org/wiki/File:0910_Oateoarthritis_Hip.jpg 
OpenStax College. (2013). File:604 Bone cells.jpg - Wikimedia Commons. Retrieved 
March 18, 2019, from https://commons.wikimedia.org/wiki/File:604_Bone_cells.jpg 
Peng, Y., Shi, K., Wang, L., Lu, J., Li, H., Pan, S., & Ma, C. (2013). Characterization of 
Osterix protein stability and physiological role in osteoblast differentiation. PloS 
One, 8(2), e56451. https://doi.org/10.1371/journal.pone.0056451 
Pérez-Campo, F. M., Santurtún, A., García-Ibarbia, C., Pascual, M. A., Valero, C., 
Garcés, C., … Riancho, J. A. (2016). Osterix and RUNX2 are Transcriptional 
Regulators of Sclerostin in Human Bone. Calcified Tissue International, 99(3), 302–
309. https://doi.org/10.1007/s00223-016-0144-4 
Pocock, N. A., Eisman, J. A., Hopper, J. L., Yeates, M. G., Sambrook, P. N., & Eberl, S. 
(1987). Genetic determinants of bone mass in adults. A twin study. The Journal of 
Clinical Investigation, 80(3), 706–710. https://doi.org/10.1172/JCI113125 
Raggatt, L. J., & Partridge, N. C. (2010). Cellular and molecular mechanisms of bone 
remodeling. The Journal of Biological Chemistry, 285(33), 25103–25108. 
https://doi.org/10.1074/jbc.R109.041087 
Ralston, S. H., & de Crombrugghe, B. (2006). Genetic regulation of bone mass and 
susceptibility to osteoporosis. Genes & Development, 20(18), 2492–2506. 
https://doi.org/10.1101/gad.1449506 
Rcragun. (2009). File:Percentage of US Population Over Age 65 1950-2050.png - 
 50 
Wikimedia Commons. Retrieved March 18, 2019, from 
https://commons.wikimedia.org/wiki/File:Percentage_of_US_Population_Over_Age
_65_1950-2050.png 
Sebastian, A., & Loots, G. G. (2017). Transcriptional control of Sost in bone. Bone, 96, 
76–84. https://doi.org/10.1016/J.BONE.2016.10.009 
Siddiqui, J. A., & Partridge, N. C. (2016). Physiological Bone Remodeling: Systemic 
Regulation and Growth Factor Involvement. Physiology, 31(3), 233–245. 
https://doi.org/10.1152/physiol.00061.2014 
Smith, D. M., Nance, W. E., Kang, K. W., Christian, J. C., Johnston, C. C., & Jr. (1973). 
Genetic factors in determining bone mass. The Journal of Clinical Investigation, 
52(11), 2800–2808. https://doi.org/10.1172/JCI107476 
Teitelbaum, S. L. (2007). Osteoclasts: what do they do and how do they do it? The 
American Journal of Pathology, 170(2), 427–435. 
https://doi.org/10.2353/ajpath.2007.060834 
Toyosawa, S., Shintani, S., Fujiwara, T., Ooshima, T., Sato, A., Ijuhin, N., & Komori, T. 
(2001). Dentin Matrix Protein 1 Is Predominantly Expressed in Chicken and Rat 
Osteocytes But Not in Osteoblasts. Journal of Bone and Mineral Research, 16(11), 
2017–2026. https://doi.org/10.1359/jbmr.2001.16.11.2017 
Valasek, M. A., & Repa, J. J. (2005). The power of real-time PCR. Advances in 
Physiology Education, 29(3), 151–159. https://doi.org/10.1152/advan.00019.2005 
Yu, J. M., Wu, X., Gimble, J. M., Guan, X., Freitas, M. A., & Bunnell, B. A. (2011). 
Age-related changes in mesenchymal stem cells derived from rhesus macaque bone 
 51 
marrow. Aging Cell, 10(1), 66–79. https://doi.org/10.1111/j.1474-
9726.2010.00646.x 
Zhang, S., Liu, Y., & Liang, Q. (2018). Low-dose dexamethasone affects osteoblast 
viability by inducing autophagy via intracellular ROS. Molecular Medicine Reports, 
17(3), 4307–4316. https://doi.org/10.3892/mmr.2018.8461 
Zhou, X., Zhang, Z., Feng, J. Q., Dusevich, V. M., Sinha, K., Zhang, H., … de 
Crombrugghe, B. (2010). Multiple functions of Osterix are required for bone growth 
and homeostasis in postnatal mice. Proceedings of the National Academy of 
Sciences of the United States of America, 107(29), 12919–12924. 
https://doi.org/10.1073/pnas.0912855107 
  
 52 
CURRICULUM VITAE 
 53 
